CardioComm Solutions (CardioComm) is a global leader and trusted provider of innovative medical software solutions for remote monitoring of electrocardiograms (ECGs). This service is provided for consumers, hospitals, physicians and ECG monitoring services. As an innovator in remote monitoring, CardioComm uses software that has been cleared as a medical device (“SaMD”), to support m-Health and telemedicine ambulatory ECG arrhythmia monitoring markets where consistent service reliability, HIPPA compliance and EMR communications are expected.

CardioComm's core technologies involve their Global ECG Management Solutions (GEMS™) software. This software enables remote transfer, viewing, analyzing, sharing and storing of ECGs over a global virtual healthcare network accessible by physicians for the management of their patients. A cornerstone of CardioComm's platform is its ECG signal viewer, which provides flexible integrations to support open ended work flow solutions. CardioComm clients have included GE Healthcare & Philips Medical, where novel ECG management solutions have supported high-volume mobile cardiac telemetry ECG monitoring services.

CardioComm is one of a few companies that services both medical and commercial markets internationally and was the first company in Canada and the USA to be given medical device clearances for the sale of an ECG monitor directly for consumer use without a physician prescription (OTC).

The Company is ISO 13485 certified and has products cleared for sale in the US, Canada, China, Australia, the Gulf Region, India and the EU. Leveraging its strengths in connecting medical devices and hospital medical records systems, CardioComm is adding new wearable, multi-bio sign monitoring and wireless m-Health devices to their HeartCheck™ branded/compatible ECG offerings.

As an active collaborator in clinical research, R&D projects and with start-ups & academic groups, CardioComm looks to provide SaMD partnerships to help disruptive medical technologies see market readiness with reduced cycle times. Such efforts support CardioComm's intended foray into the wearable technology and m-Health markets through the introduction of its new HeartCheck™ and GEMS™ compatible consumer devices such as ECG wristbands, ECG cards, patches and shirts.

All such wearable devices will be developed to have communication compatibility with Apple and Android smartphones and tablets, with the aim to give consumers access to “medically credible” medical-wellness products at a lower cost when compared to other, non-medically credentialed products offered from competitors like Samsung, Apple and Fitbit.

CardioComm's pipeline of technologies will address the need for enhanced data quality collected for personal health monitoring, allow use in predictive analytics and provide health care professionals access to patient information whenever necessary, in a safe and reliable environment. It is such efforts to push the boundaries for meeting an unmet demand for credible m-health and consumer wellness self-monitoring technologies that has led CardioComm to be recognized by ACQ Global Awards as the "Niche Technology Company Of The Year (Healthcare / Telemed, CardioComm Solutions)."